M-protein gene-type distribution and hyaluronic acid capsule in group A Streptococcus clinical isolates in Chile: Association of emm gene markers with csrR alleles

Epidemiology and Infection

Volumn 140, Issue 7, 2012, Pages 1286-1295

  Wozniak, A ^a   Rojas, P ^a   Rodriguez C ^a   Undabarrena, A ^a   Garate, C ^a   Riedel, I ^a   Roman J C ^a   Kalergis, A M ^b   Garcia P ^a  

^a PONTIFICIA UNIVERSIDAD CATÓLICA DE CHILE   (Chile)

^b PONTIFICIA UNIVERSIDAD CATÓLICA DE CHILE   (Chile)

Author keywords

Antibiotic resistance; molecular epidemiology; Streptococcus pyogenes

Indexed keywords

ASPARAGINE; BACTERIAL DNA; ERYTHROMYCIN; GLUTAMINE; HISTIDINE; HYALURONIC ACID; ISOLEUCINE; LEUCINE; M PROTEIN; THREONINE; VIRULENCE FACTOR;

ALLELE; AMINO ACID SUBSTITUTION; ANTIBIOTIC RESISTANCE; ANTIBIOTIC SENSITIVITY; ARTICLE; ASIA; BACTERIAL GENE; BACTERIAL MEMBRANE; BACTERIAL VIRULENCE; BACTERIUM ISOLATE; CHILE; CSRR GENE; DEVELOPING COUNTRY; DNA EXTRACTION; EMM GENE; GENE MUTATION; HORIZONTAL GENE TRANSFER; MARKER GENE; NONHUMAN; NUCLEOTIDE SEQUENCE; PACIFIC ISLANDS; PHENOTYPE; POLYMERASE CHAIN REACTION; SEQUENCE ANALYSIS; SOUTH AND CENTRAL AMERICA; STREPTOCOCCAL PHARYNGITIS; STREPTOCOCCUS GROUP A; STREPTOCOCCUS PYOGENES;

ALLELES; ANTIGENS, BACTERIAL; BACTERIAL CAPSULES; BACTERIAL OUTER MEMBRANE PROTEINS; BACTERIAL PROTEINS; CARRIER PROTEINS; CHILE; GENOTYPE; HUMANS; HYALURONIC ACID; PHENOTYPE; REPRESSOR PROTEINS; STATISTICS AS TOPIC; STREPTOCOCCAL INFECTIONS; STREPTOCOCCUS PYOGENES; VIRULENCE FACTORS;

EID: 84861097414     PISSN: 09502688     EISSN: 14694409     Source Type: Journal    
DOI: 10.1017/S0950268811001889     Document Type: Article

References (45)

1. Carapetis JR, et al. The global burden of group A streptococcal diseases. Lancet Infectious Diseases 2005; 5: 685-694.
2. Baxter F, McChesney J. Severe group A streptococcal infection and streptococcal toxic shock syndrome. Canadian Journal of Anaesthesia 2000; 47: 1129-1140.
3. Cartwright K, et al. A cluster of cases of streptococcal necrotizing fasciitis in Gloucestershire. Epidemiology and Infection 1995; 115: 387-397.
4. Berrios X, et al. Post-streptococcal acute glomerulonephritis in Chile -20 years of experience. Pediatric Nephrology 2004; 19: 306-312.
5. Schwartz B, Facklam RR, Breiman RF. Changing epidemiology of group A streptococcal infection in the USA. Lancet 1990; 336: 1167-1171.
6. Kaplan EL, Johnson DR, Cleary PP. Group A streptococcal serotypes isolated from patients and sibling contacts during the resurgence of rheumatic fever in the United States in the mid-1980s. Journal of Infectious Diseases 1989; 159: 101-103.
7. Stollerman GH, Dale JB. The importance of the group a streptococcus capsule in the pathogenesis of human infections : A historical perspective. Clinical Infectious Diseases 2008; 46: 1038-1045.
8. Schrager HM, Rheinwald JG, Wessels MR. Hyaluronic acid capsule and the role of streptococcal entry into keratinocytes in invasive skin infection. Journal of Clinical Investigation 1996; 98: 1954-1958.
9. Dalton TL, Hobb RI, Scott JR. Analysis of the role of CovR and CovS in the dissemination of Streptococcus pyogenes in invasive skin disease. Microbial Pathogenesis 2006; 40: 221-227.
10. Heath A, et al. A two-component regulatory system, CsrR-CsrS, represses expression of three Streptococcus pyogenes virulence factors, hyaluronic acid capsule, streptolysin S, and pyrogenic exotoxin B. Infection and Immunity 1999; 67: 5298-5305.
11. Engleberg NC, et al. Spontaneous mutations in the CsrRS two-component regulatory system of Streptococcus pyogenes result in enhanced virulence in a murine model of skin and soft tissue infection. Journal of Infectious Diseases 2001; 183: 1043-1054.
12. Fischetti VA, Hodges WM, Hruby DE. Protection against streptococcal pharyngeal colonization with a vaccinia : M protein recombinant. Science 1989; 244: 1487-1490.
13. Efstratiou A. Group A streptococci in the 1990s. Journal of Antimicrobial Chemotherapy 2000; 45 (Suppl.) : 3-12.
14. Centers for Disease Control and Prevention. Streptococcus pyogenes emm sequence database (http://www. cdc.gov/ncidod/biotech/strep/emmtype-proportions. htm). Accessed August 2011.
15. Richardson LJ, et al. Diversity of emm sequence types in group A beta-haemolytic streptococci in two remote northern territory indigenous communities: Implications for vaccine development. Vaccine 2010; 28: 5301-5305.
16. Centers for Disease Control and Prevention. Streptococcus pyogenes emm sequence Database (http://www. cdc.gov/ncidod/biotech/strep/strepindex.htm). Accessed January 2011.
17. Whatmore AM, et al. Non-congruent relationships between variation in emm gene sequences and the population genetic structure of group A streptococci. Molecular Microbiology 1994; 14: 619-631.
18. Sneath P, Sokal R. Numerical Taxonomy. San Francisco: Freeman, 1973.
19. Tamura K, Nei M, Kumar S. Prospects for inferring very large phylogenies by using the neighbor-joining method. Proceedings of the Natural Academy of Sciences USA 2004; 101: 11030-11035.
20. Tamura K, et al. MEGA4: Molecular evolutionary genetics analysis (MEGA) software version 4.0. Molecular Biology and Evolution 2007; 24: 1596-1599.
21. Darmstadt GL, et al. Role of group A streptococcal virulence factors in adherence to keratinocytes. Infection and Immunity 2000; 68: 1215-1221.
22. Ashbaugh CD, Alberti S, Wessels MR. Molecular analysis of the capsule gene region of group A Streptococcus: The hasAB genes are sufficient for capsule expression. Journal of Bacteriology 1998; 180: 4955-4959.
23. Clinical and Laboratory Standards Institute (CLSI). Methods for dilution antimicrobial susceptibility tests for bacteria that grow aerobically. Wayne, PA: CLSI 2006.
24. Clinical and Laboratory Standards Institute (CLSI). Performance standards for antimicrobial susceptibility testing, twentieth informational supplement, 2010.M100-S20, Vol. 30, No. 1.
25. Jadoun J, Eyal O, Sela S. Role of CsrR, hyaluronic acid, and SpeB in the internalization of Streptococcus pyogenes M type 3 strain by epithelial cells. Infection and Immunity 2002; 70: 462-469.
26. Johnson DR, Stevens DL, Kaplan EL. Epidemiologic analysis of group A streptococcal serotypes associated with severe systemic infections, rheumatic fever, or uncomplicated pharyngitis. Journal of Infectious Diseases 1992; 166: 374-382.
27. Espinosa LE, et al. M protein gene type distribution among group A streptococcal clinical isolates recovered in Mexico City, Mexico, from 1991 to 2000, and Durango, Mexico, from 1998 to 1999: Overlap with type distribution within the United States. Journal of Clinical Microbiology 2003; 41: 373-378.
28. Sagar V, et al. Comparative analysis of emm type pattern of Group A Streptococcus throat and skin isolates from India and their association with closely related SIC, a streptococcal virulence factor. BMC Microbiology 2008; 8: 150.
29. Lopardo HA, et al. Six-month multicenter study on invasive infections due to Streptococcus pyogenes and Streptococcus dysgalactiae subsp. equisimilis in Argentina. Journal of Clinical Microbiology 2005; 43: 802-807.
30. O'Loughlin RE, et al. The epidemiology of invasive group A streptococcal infection and potential vaccine implications : United States, 2000-2004. Clinical Infectious Diseases 2007; 45: 853-862.
31. Creti R, et al. emm Types, virulence factors, and antibiotic resistance of invasive Streptococcus pyogenes isolates from Italy : What has changed in 11 years ? Journal of Clinical Microbiology 2007; 45: 2249-2256.
32. Smeesters PR, et al. Differences between Belgian and Brazilian group A Streptococcus epidemiologic landscape. PLoS One 2006; 1: E10.
33. Bahnan W, et al. emm typing, antibiotic resistance and PFGE analysis of Streptococcus pyogenes in Lebanon. Journal of Medical Microbiology 2011; 60: 98-101.
34. Miyoshi-Akiyama T, et al. Use of DNA arrays to identify a mutation in the negative regulator, csrR, responsible for the high virulence of a naturally occurring type M3 group A streptococcus clinical isolate. Journal of Infectious Diseases 2006; 193: 1677-1684.
35. Bessen DE, et al. Genetic linkage of exotoxin alleles and emm gene markers for tissue tropism in group A streptococci. Journal of Infectious Diseases 1999; 179: 627-636.
36. Radice M, et al. First class A carbapenemase isolated from enterobacteriaceae in Argentina. Antimicrobial Agents and Chemotherapy 2004; 48: 1068-1069.
37. Tokumoto MB, et al. Emergence of communityacquired methicillin-resistant Staphylococcus aureus (CA-MRSA) paediatric clone among skin and softtissue infections in Buenos Aires. International Journal of Antimicrobial Agents 2007; 30: 469-471.
38. Benoit SR, et al. Community strains of methicillinresistant Staphylococcus aureus as potential cause of healthcare-Associated infections, Uruguay, 2002-2004. Emerging Infectious Diseases 2008; 14: 1216-1223.
39. Alvarez CA, et al. Nosocomial infections caused by community-Associated methicillin-resistant Staphylococcus aureus in Colombia. American Journal of Infection Control 2010; 38: 315-318.
40. Villegas MV, et al. First detection of the plasmidmediated class A carbapenemase KPC-2 in clinical isolates of Klebsiella pneumoniae from South America. Antimicrobial Agents and Chemotherapy 2006; 50: 2880-2882.
41. Peirano G, et al. Carbapenem-hydrolysing betalactamase KPC-2 in Klebsiella pneumoniae isolated in Rio de Janeiro, Brazil. Journal of Antimicrobial Chemotherapy 2009; 63: 265-268.
42. Ribeiro A, et al. First report of infection with community-Acquired methicillin-resistant Staphylococcus aureus in South America. Journal of Clinical Microbiology 2005; 43: 1985-1988.
43. Palavecino E, et al. Prevalence and mechanisms of macrolide resistance in Streptococcus pyogenes in Santiago, Chile. Antimicrobial Agents and Chemotherapy 2001; 45: 339-341.
44. Rodríguez C, et al. Analysis of resistance phenotypes and genotypes of clinical isolates of Streptococcus pyogenes in Chile over a 10-year period. Revista Médica de Chile (in press).
45. Hu MC, et al. Immunogenicity of a 26-valent group A streptococcal vaccine. Infection and Immunity 2002; 70: 2171-2177.